About Avertix

Our Story

Avertix was founded in 2001 by Drs. Robert, Tim and David Fischell, active serial entrepreneurs and inventors of medical technologies. In 1999, the company filed its first of more than 50 issued US patents relating to detecting cardiac events and patient alerting, with the company’s first human implant occurring in 2005.

Our company has developed the Guardian System, which is the first and only FDA approved solution designed to detect and warn patients of acute thrombotic coronary occlusion.

CMS awarded the Guardian a Transitional Pass Through status in November 2021 which became effective January 1, 2022.

Management Team

Ross Haghighat, Executive Chairman
Timothy P. Moran, President and Chief Executive Officer
Philip L. Tom, Executive Vice President and Chief Financial Officer
David L. Keenan, Chief Technology Officer
Bryan Finley, SVP, Global Sales
Holly S. Windler, SVP, Global Marketing

Investor Relations


For investor professional information please contact us

News & Press Releases

Avertix Data Presented at TCT 2023 Shows 150% Increase in Medication Adjustments of Antiarrhythmics for High-Risk Heart Attack Survivors
Avertix to Present at Two Upcoming Investor Conferences in September 2023
Heart & Rhythm Institute of Trinity and Avertix Announce Partnership to Improve Cardiac Care and Patient Monitoring
Renown Cardiologist and Professor Ian T. Meredith, MD to Join Avertix Medical’s Board of Directors
Avertix’s Guardian™ System, First and Only FDA-Approved Implantable Heart Attack Detection and Warning System, Now Available at AdventHealth Orlando
Avertix to Participate in the Sidoti Summer Small Cap Conference
Avertix Showcases Guardian at Three Prestigious Conferences
AngelMed is now Avertix
Avertix Announces CMS Approval of Transitional Pass-Through (TPT) Payment Category For The Guardian™
Avertix Announces First Commercial Implantation of Real-Time Heart Attack Warning System
Avertix Announces FDA Approval of the Enhanced Real-Time Cardiac Monitor for Acute Coronary Syndrome (ACS) Events


SCAI 2024 Scientific Sessions
May 2-4, 2024
Long Beach, CA
Heart Rhythm 2024
May 16-19, 2024
Boston, MA
TCT 2024
October 27-30, 2024
Washington, DC
Cantor Fitzgerald Global Healthcare Conference
Sidoti Small Cap Conference
Sidoti Summer Small Cap Conference


Avertix is looking for employees who share our core values and who are looking for a challenging career opportunity. We are committed to finding, attracting, and retaining a talented workforce. We reward expertise with professional growth and opportunity, an excellent salary, and an extensive benefits package.

Submit your Avertix Employment Application and resume to our Human Resources Department at resumes@avertix.com to be considered for an available position. Be sure to reference the staff requisition number (shown at the top of position pages) when applying for a position with Avertix.

Current Openings:

Avertix is an Equal Opportunity Employer.

To be considered for an opening:

Download and complete the Avertix Employment Application
Email both to